Pamrevlumab and idiopathic pulmonary fibrosis
Release Date:
Dr. Luca Richeldi discusses a trial looking at pamrevlumab, an anti-connective tissue growth factor therapy for the treatment of idiopathic pulmonary fibrosiContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
Pamrevlumab and idiopathic pulmonary fibrosis